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The von Hippel-Lindau tumor suppressor protein
(VHL) recruits a Cullin 2 (Cul2) E3 ubiquitin ligase to
downregulate HIF-1a, an essential transcription fac-
tor for the hypoxia response. Mutations in VHL lead
to VHL disease and renal cell carcinomas. Inhibition
of this pathway to upregulate erythropoietin produc-
tion is a promising new therapy to treat ischemia and
chronic anemia. Here, we report the crystal structure
of VHL bound to aCul2 N-terminal domain, Elongin B,
and Elongin C (EloC). Cul2 interacts with both the
VHL BC box and cullin box and a novel EloC site.
Comparison with other cullin E3 ligase structures
shows that there is a conserved, yet flexible, cullin
recognition module and that cullin selectivity is influ-
enced by distinct electrostatic interactions. Our
structure provides a structural basis for the study
of the pathogenesis of VHL disease and rationale
for the design of novel compounds that may modu-
late cullin-substrate receptor interactions.
INTRODUCTION
Cullin-RING E3 ubiquitin ligases (CRLs) are critical for targeting
cellular proteins for ubiquitin-dependent degradation through
the 26S proteasome. This pathway is a central mechanism to
control protein turnover during many cellular processes
(Hershko and Ciechanover, 1998). It is also exploited by patho-
gens such as HIV to degrade immune factors upon infection
(Ahn et al., 2012; Yu et al., 2003). The best-characterized CRLs
are the SCF (Skp1-Cul1-F box) and ECS (EloC-Cul2/5-SOCS
box) complexes (Petroski and Deshaies, 2005). An ECS ubiquitin
ligase consists of a cullin protein that serves to scaffold multiple
subunits: a RING finger protein (Rbx1 or Rbx2), which binds to E2
ubiquitin conjugating enzymes, substrate receptors (such as von
Hippel-Lindau tumor suppressor protein [VHL] or SOCS box pro-
teins), which recognize target proteins, and adaptor proteins
(such as Elongin B [EloB] and Elongin C [EloC]), which bridge
the substrate receptor to the cullin protein (Sarikas et al.,
2011). For example, the VHL E3 ligase is composed of Cullin 2Structure 23,(Cul2) (Pause et al., 1997), which interacts with VHL-EloB-EloC
at its N terminus and Rbx1 at its C terminus (Kamura et al., 1999).
VHL plays an important role in regulating the cellular response
to oxygen levels and consequently a role in the development of
renal cancer, cardiovascular disease, ischemia, and chronic
anemia (Kaelin, 2008). Under normoxic conditions, VHL targets
the transcription factor hypoxia-inducible factor-1a (HIF-1a) for
ubiquitylation and subsequent degradation by the proteasome
(Ohh et al., 2000). The interaction between VHL and HIF-1a
does not occur under hypoxic conditions, allowing HIF-1a to
activate transcription of genes that drive processes such as
angiogenesis and erythropoiesis (Ivan et al., 2001). Mutations
in VHL that disrupt the ubiquitylation of HIF-1a cause VHL dis-
ease and renal cell carcinomas, with many mutations in the re-
gion of VHL that interacts with EloC/Cul2 (Figure 1) (Kaelin,
2002; Nordstrom-O’Brien et al., 2010). Conversely, inhibition of
this pathway increases endogenous erythropoietin production
and is under investigation as a new therapy to treat chronic ane-
mia associated with kidney disease and cancer chemotherapy
(Buckley et al., 2012; Harten et al., 2010; Muchnik and Kaplan,
2011; Ong and Hausenloy, 2012; Rabinowitz, 2013).
VHL also interacts with fibronectin to promote formation of the
extracellular matrix (ECM) in an HIF-independent manner (Ohh
et al., 1998). The ECM, which comprisesmany proteins including
fibronectin, plays vital roles in cell migration, proliferation,
signaling, and other processes (Hynes, 2009). The VHL-fibro-
nectin interaction requires neddylation of VHL at K159 (Stickle
et al., 2004) and is mutually exclusive to VHL binding to Cul2
(Russell and Ohh, 2008). Defective organization of the ECM
contributes to angiogenesis and tumorigenesis in an HIF-inde-
pendent manner (Kurban et al., 2006).
VHL is a member of the VHL box family of E3 substrate recep-
tors. The VHL box is similar to the SOCS box (Mahrour et al.,
2008). We will refer to them collectively as SOCS boxes for brev-
ity. The SOCS box is composed of three helices, which are
divided into a BC box and a cullin box. The BC box spans the
first helix and mediates the association with EloB and EloC
(EloBC). The cullin box consists of the remaining helix-turn-helix
motif and interacts with cullins. The structures of various SOCS-
box-containing proteins (ASB9, SOCS2, SOCS3, SOCS4,
GUSTAVUS, VHL, and Vif) bound to EloBC show that SOCS
boxes are in similar conformations and use a conserved mecha-
nism to bind EloBC (Babon et al., 2008; Bullock et al., 2006,
2007; Guo et al., 2014; Kim et al., 2013; Muniz et al., 2013;441–449, March 3, 2015 ª2015 Elsevier Ltd All rights reserved 441
Figure 1. Sequence Alignment of VHL BC Box and Cullin Box to
other Cul2 and Cul5 Binding Proteins
The regions for the BC box and cullin box are marked. Conserved residues are
highlighted and the Fp (F indicates a hydrophobic residue) motif is shown.
VHL missense mutations associated with VHL disease are shown in red.
Table 1. Data Collection and Refinement Statistics
Data Collection
Wavelength (A˚) 1.0750
Space group P3221
Cell Dimensions
a, b, c (A˚) 108.28, 108.28, 213.77
a, b, g () 90.00, 90.00, 120.00
Molecules/asymmetric unit 1
Resolution (A˚) 48.3–3.2 (3.3–3.2)
Unique reflections 24,321
Rmerge 0.084 (1.6)
I/sI 16.4 (1.1)
Completeness (%) 99.8 (99.9)
Redundancy 5.8 (5.9)
CC1/2 1 (0.49)
Refinement
Number of nonhydrogen atoms 3903
Rwork/Rfree (%) 22.1/25.0 (35.6/39.8)
Average B factor 123
Rmsd
Bond lengths (A˚) 0.011
Bond angles () 1.8
Ramachandran Analysis
Preferred regions (%) 94.6
Allowed regions (%) 4.8
Outliers (%) 0.6
Statistics in parentheses indicate those for the highest resolution shell.Stanley et al., 2008; Thomas et al., 2013; Woo et al., 2006). How-
ever, different SOCS box proteins interact with different cullins.
For example, VHL binds Cul2 and SOCS2 binds Cul5. The cullin
box dictates binding to either Cul2 or Cul5, where a 2-amino acid
region within the cullin box, theVpmotif (V denotes a hydropho-
bic residue), is important for cullin binding in both cases (Figure 1)
(Hilton et al., 1998; Kamura et al., 2004). Recently, crystal struc-
tures of SOCS2-EloBC-Cul5 (Kim et al., 2013) and Vif-EloBC-
Cul5 (Guo et al., 2014) have been reported, illuminating how
different regions of Cul5 are used for its recruitment to different
E3 ligases.
The detailed mechanism of how different cullin proteins are re-
cruited to specific E3 ubiquitin ligases remains largely unknown.
This is partially because of the lack of structural information on
any Cul2 complex. It is particularly intriguing that Cul2 and
Cul5 bind the same adaptor proteins, EloBC, but recruit different
substrate receptors with very similar cullin box sequences (Fig-
ure 1) (Mahrour et al., 2008). Here, we report the crystal structure
of VHL-EloBC bound to an N-terminal domain of Cul2, which
reveals how Cul2 recognizes the interface between VHL and
EloC. Our results provide insight into how cullins select adaptor
proteins and substrate receptors in ECS ubiquitin ligases and
establish a structural basis for a better understanding of the
pathogenesis of VHL disease.
RESULTS
Structure of the VHL-EloBC-Cul2 Complex
To investigate how VHL recruits Cul2, we coexpressed VHL (res-
idues 1–213), EloB (residues 1–118), EloC (residues 17–112), and
an N-terminal segment of Cul2 (Cul2N) spanning the first cullin
repeat (residues 1–163), the minimal domain required for binding
to VHL (Pause et al., 1999). The quaternary complex was purified
and its crystal structure was determined at 3.2 A˚ resolution
(Table 1). The VHL-EloBC-Cul2N structure has a tripod shape,
with EloC located in the center of the quaternary complex and
the other components at each end (Figure 2A). Cul2 is recruited
to VHL-EloBC through an interaction between the N-terminal re-
gion of Cul2 and both EloC and VHL. Cul2 binding induces a
structuring of the EloC loop containing residues 48–57, which
makes contact with Cul2 and is not involved in any crystal con-442 Structure 23, 441–449, March 3, 2015 ª2015 Elsevier Ltd All rightacts. This loop is unstructured in the VHL-EloBC ternary com-
plex (Stebbins et al., 1999). Regions of EloC surrounding this
loop also interact with Cul2. Apart from the ordering of this
loop, the conformation of the VHL-EloBC subcomplex remains
the same in the presence or absence of Cul2, with a Ca atom
root-mean-square deviation (rmsd) of 0.8 A˚ (Figure 2C) (Hon
et al., 2002; Min et al., 2002; Stebbins et al., 1999). The formation
of the quaternary complex is driven by hydrophobic and electro-
static interactions at the interfaces between Cul2 and both VHL
and EloC. The total buried surface area involving Cul2 interfaces
is 1270 A˚2 (322 A˚2 between Cul2 and VHL and 944 A˚2 between
Cul2 and EloC). The BC box (residues 157–170) and cullin box
(residues 175–190) of VHL interact with both EloC and Cul2 (Fig-
ure 2B). VHL residues 1–59 are disordered and not observed in
the structure.
Structural comparison of Cul2 with other cullin proteins re-
veals that they share a conserved cullin repeat structure and
contain flexible N termini, which play different roles in CRL for-
mation (Figure 2D). Cul2 is the sixth member of the cullin family
with a solved structure (after Cul1, Cul5, Cul3, Cul4A, and
Cul4B) (Angers et al., 2006; Babon et al., 2009; Canning et al.,
2013; Errington et al., 2012; Fischer et al., 2011; Guo et al.,
2014; Kim et al., 2013; Muniz et al., 2013; Zheng et al., 2002).
The first cullin repeat of Cul2 adopts the canonical six-helix cullin
fold, which superimposes well with that of the other cullins (rmsd
1.0–1.4 A˚ for Ca atoms). However, both the sequences and
structures of cullin N termini are highly variable (Figures 2D andts reserved
Figure 2. Structure of the VHL-EloB-EloC-
Cul2 Quaternary Complex
(A) Surface representation of the complex. VHL,
EloB, EloC, and Cul2 are colored in gray, yellow,
cyan, and green, respectively.
(B) (Left) Ribbon representation with the a helices
of Cul2 labeled and the Cul2 N terminus marked by
a sphere. (Right) Close-up view showing the con-
tact made by the BC box and cullin box of VHL (the
boxed region in left panel).
(C) Structural superposition of the VHL-EloBC
complexes with or without bound Cul2. The VHL-
EloBC ternary complex without Cul2 (PDB ID:
1LM8) is shown in light blue. VHL-EloBC of the
quaternary complex is shown in pink with Cul2 in
green. The EloC loop, which becomes ordered
upon binding of Cul2, is shown in red.
(D) Comparison of the first cullin repeats of Cul1
(PDB ID: 1LDK), Cul2, Cul3 (PDB ID: 4APF), Cul4A
(PDB ID: 2HYE), and Cul5 (PDB ID: 4JGH) colored
in cyan, green, orange, dark gray, and magenta,
respectively. The N termini of the cullins are
marked by spheres.
(E) Sequence alignment of Cul1–5. Highlighted re-
gions represent visible, ordered residues found in
their respective structures. Helix 1 is marked.2E). Previously, the long, structured N-terminal extensions of
Cul3, Cul4A, and Cul4B were known to be involved in the forma-
tion of their respective E3 ligase complexes, whereas Cul1 and
Cul5 have short, structured N-terminal extensions, which are
not involved in complex formation (Guo et al., 2014; Kim et al.,
2013; Zheng et al., 2002). In contrast, the Cul2 N-terminal exten-
sion is short but still plays an important role in complex formation
(discussed below).
Cul2 and Cul5 Interact with the Same EloC Interface
Differently
Cul2 interacts with EloC through a conserved interface site be-
tween the adaptor protein and the cullin scaffold in ECS ubiquitin
ligases, however,with a substantially different subunit orientation
and contact pattern at the interaction interface (Figure 3). EloC is
the adaptor protein for both Cul2 and Cul5 CRLs, and it is struc-
turally similar to Skp1, the adaptor protein for the Cul1 CRLs
(Zheng et al., 2002). Previously, EloC-Cul5 and Skp1-Cul1 have
been shown to align well structurally (Kim et al., 2013). We
compared our EloC-Cul2 structure with that of EloC-Cul5 by
superimposing the common EloC component. The EloC-cullin
interaction in both cases is mediated by contacts between heli-
ces a2, a4, and a5 of the cullins and a surface on EloC consisting
of residues 48–65 and 104–112 (Figure 3B). Despite the common
interface site, the two EloC-interacting cullins have substantially
different orientations (with a relative 16 rotation). Conse-
quently, Cul2-EloC and Cul5-EloC interfaces involve a distinctly
different pattern of contacts, with some EloC residues engaging
residues at different relative positions of Cul5 or Cul2 (Figure 3B).
For example, residue P5 of Cul2 contacts M105 of EloC, while
this interaction is absent between Cul5 and EloC due to differ-
ences at the cullin N terminus. Instead,W53 located at the begin-
ning of helix a2 of Cul5 forms stacking interaction with EloC
M105. This results in a shift of Cul5 helix a2 a few angstroms
toward EloC from the corresponding position in Cul2 (Figure 3C).Structure 23,The N-terminal extension of Cul2 plays a critical role in the
formation of the VHL E3 ligase and likely contributes to the
observed difference in the EloC-interacting modes when
compared with that of Cul5. Specifically, residue L3 of Cul2 in-
serts into a hydrophobic pocket formed by EloC residues I65,
M105, A106, and F109 (Figure 3D). As the N-terminal extension
is highly conserved across all Cul2 orthologs (Figure 4E), we
sought to confirm its importance for complex formation. We per-
formed in vitro pull-down binding assays with glutathione
S-transferase (GST)-tagged VHL and different Cul2N constructs.
A maltose binding protein (MBP) tag was added to Cul2N to
improve its solubility. The result shows that a single mutation,
L3G on Cul2, drastically reduced the binding of Cul2 to VHL-
EloBC, highlighting the importance of this conserved Cul2 resi-
due (Figure 3E). This is consistent with the previous report that
implicates the first four residues of Cul2 in the assembly of the
E3 ligase (Pause et al., 1999). EloC residue F109, which interacts
with the Cul2 N-terminal extension, is also necessary for Cul5
binding (Muniz et al., 2013), but Cul5 contains different N-termi-
nal residues, which do not interact with EloC. This indicates that
Cul2 and Cul5 evolved specific ways to recognize and engage
EloC for the assembly of their respective E3 ligases.
Cul2 Interacts with Both the VHL BC Box and the
Cullin Box
Cul2 engages in important interactions with VHL at two sites. The
first site involves theVpmotif of VHL, which has previously been
shown to be important for cullin binding (Kamura et al., 2004).
Our structure reveals that residue V181 of this motif in VHL
(180IV181, Figure 1) makes a three-way hydrophobic contact
with residues P5 and V47 of Cul2 and M105 of EloC (Figure 4A).
At the second interaction site, both the BC box and cullin box of
VHL make additional contacts with residues on helix a5 of Cul2
through an electrostatic network (Figure 4B). Residue K159 of
the VHL BC box and residue D187 of the VHL cullin box form441–449, March 3, 2015 ª2015 Elsevier Ltd All rights reserved 443
Figure 3. Different Cul2 and Cul5 Interac-
tions with EloC
(A) Superposition of the Cul5-EloC (PDB ID: 4JGH)
and the current Cul2-EloC structures in ribbon
representations.
(B) (Top) Surface representations of EloC bound to
either Cul2 (left) or Cul5 (right). Residues involved in
the respective cullin interaction are shown in
orange. (Bottom) Surface representations of Cul2
and Cul5 with residues involved in EloC interactions
shown in blue and yellow, respectively.
(C) Differential recognition of EloC M105 by Cul2
(green) and Cul5 (magenta), in the boxed region of
(A). EloC M105 bound to Cul2 or Cul5 is shown in
green or magenta, respectively.
(D) L3 of Cul2 inserts into a hydrophobic pocket
of EloC. The N terminus of Cul2 is shown as
a sphere.
(E) GST affinity pull-down assay to assess the
contribution of Cul2 L3 in binding to VHL-EloBC.hydrogen-bonding and salt bridge interactions with residues
Q111 and K114 of Cul2. These combined interactions enable
VHL to recruit Cul2 to the E3 ligase.
We validated the importance of the VHL-Cul2 interface resi-
dues by GST affinity pull-down assays (Figure 4C). The VHL
and Cul2 interface residues identified above are well conserved
in Cul2 and VHL orthologs (Figure 4E). We generated the VHL
V181G mutant to assess the contribution of the hydrophobic
interaction provided by residue V181. Consistent with its impor-
tant role in cullin binding (Kamura et al., 2004), this mutant sub-
stantially reduced VHL binding to Cul2 but retained binding to
EloBC (Figure 4C). We next investigated the contribution of the
VHL-Cul2 electrostatic interactions for formation of the E3 ligase.
Either the Q111L mutant of Cul2 or the D187K mutant of VHL
drastically reduced binding between Cul2 and VHL-EloBC (Fig-
ure 4C). As expected from our structural analysis, Cul2 Q111L
disrupted two hydrogen bonds to VHL D187 and K159, while
VHL D187K disrupted the interactions to Cul2 Q111 and K114
(Figure 4B). Two other mutations in the electrostatic network,
Cul2 K114E and VHL K159E, also had a clear decrease in
VHL-Cul2 assembly (Figure 4C). It should be noted that the
binary interactions of either Cul2-VHL or Cul2-EloC are known
to be weak (Lonergan et al., 1998). The combined interactions
of the Cul2-VHL and Cul2-EloC interfaces are required for forma-
tion of the E3 ubiquitin ligase complex.
Our structural and biochemical data provide strong evidence
that K159 plays an additional role in VHL functions. As described
above, VHL K159 is part of an electrostatic network at the VHL-
Cul2 interface and contributes to complex formation. Indepen-
dent from this function, neddylation of VHL at K159 is required
for the VHL-fibronectin interaction and loss of this interaction is
oncogenic (Russell and Ohh, 2008; Stickle et al., 2004). Our
data shed light on how this residue performs an additional role.
Mutation of this residue abolishes neddylation and also de-
creases Cul2 binding, which are both tumorigenic. Interestingly,
this residue lies within the BC box of VHL, representing the first
observation of the involvement of a BC box in cullin recruitment.444 Structure 23, 441–449, March 3, 2015 ª2015 Elsevier Ltd All righThe K159E mutation in VHL is a cause of VHL disease (Zbar
et al., 1996). Intriguingly, we observed that the binding of the
VHL K159E mutant to Cul2 was pH dependent, where binding
was drastically reduced at lower pH (pH 6), in contrast to the
modest reduction at neutral pH (pH 7.2). In contrast, binding of
Cul2 to wild-type VHL was minimally affected at different pH
values tested (Figure 4D).Whether this pHdependence has other
physiological consequences remains to be seen, even although
fluctuations of intracellular pH, such as during cell growth, have
been observed (Dechant et al., 2010, 2014; Orij et al., 2012).
Comparison of Cullin-Substrate Receptor Architecture
and Association
To gain a better understanding of how cullins associate with sub-
strate receptors in CRLs, we compared the respective cullin in-
terfaces in the VHL-EloC-Cul2, SOCS2-EloC-Cul5 (Kim et al.,
2013), Vif-EloC-Cul5 (Guo et al., 2014), Skp2-Skp1-Cul1 (Zheng
et al., 2002), and KLHL11-Cul3 (Canning et al., 2013) complexes
(Figure 5). The structureswere overlaid by superimposing the ho-
mologous regions of EloC, Skp1, and KLHL11 (Canning et al.,
2013; Zheng et al., 2002). The overall architectures are similar,
with a conserved interface between the cullin and the respective
adaptor protein (EloC/Skp1/KLHL11) and substrate receptor
(VHL/Skp2/SOCS2/Vif/KLHL11). KLHL11 serves as both the
adaptor protein and substrate receptor for Cul3 (Figure 5A). A
homologous helical-bundle structure formed by a helices from
both the adaptor proteins and substrate receptors constitutes
one side of the interface. Across the complexes, the orientation
between a cullin and its substrate adaptor varies, ranging from a
rotation of 1–16 relative to the Cul2 complex. The arrangement
of Vif is different from those of the others because it lacks a
canonical SOCS box. Vif interacts with Cul5 using a zinc-finger
region upstream of the SOCS box (Mehle et al., 2006; Xiao
et al., 2006), even though a cullin box motif is present in the
protein. Nevertheless, a similar three-protein interface is formed
involving interactions at the end of helix a2 of all the cullins
(Figure 5B). In each case, hydrophobic packing or stackingts reserved
Figure 4. Interactions between VHL and Cul2
(A) Three-way interaction between the VHL Vp motif, EloC, and helix a2 of Cul2.
(B) (Left) Binary interaction between VHL and helix a5 of Cul2. (Right) Close-up view of the electrostatic network between VHL and Cul2 (boxed region in left).
Electrostatic potentials of VHL and Cul2 are shown as semitransparent surfaces and residues involved are shown as sticks. Dashed lines represent hydrogen
bonds or salt bridges.
(C and D) GST pull-down assays assessing contribution of Cul2 and VHL residues for formation of the quaternary complex. Assays were done at pH 7.2 unless
otherwise indicated.
(E) Sequence alignments of Cul2 and VHL orthologs. Asterisks denote important residues identified by the structural analysis of the VHL-EloBC-Cul2N quaternary
complex.interactions stabilize the association between the cullin and the
adaptor protein/substrate receptor. Notably, Cul2 and Cul3
both utilize residues on their N-terminal extensions to stabilize
the interaction involving helix a2. Helix a2 of Cul2 is further
away from the substrate receptor compared with that of the
similar Cul5 or Cul1. As described above, this is likely due to
the unique interaction involving the N terminus of Cul2.
An electrostatic interaction between a specific substrate re-
ceptor and the respective cullin may potentially contribute toStructure 23,cullin selection in CRL formation. In the case of VHL-Cul2,
SOCS2-Cul5, and Skp2-Cul1, there is charge complementarity
at the interface between the substrate receptor and helix a5 of
the cullin. The importance of the electrostatic interaction is sup-
ported by our data, which show that a mutation of VHL D187K or
Cul2 K114E at the interface disrupted the VHL-Cul2 interaction.
For KLHL11-Cul3, both helix a5 and the loop following helix a2 of
Cul3 create a positively charged surface, similar to Cul1 and
Cul2, which makes polar interactions with KLHL11 via the441–449, March 3, 2015 ª2015 Elsevier Ltd All rights reserved 445
Figure 5. Comparison of the overall CRL Architecture and Cullin-Adaptor Protein/Substrate Receptor Interactions
Residues involved in interactions are shown as sticks.
(A) The cullin-adaptor protein/substrate receptor binding regions of VHL-EloC-Cul2, SOCS2-EloC-Cul5 (PDB ID: 4JGH), Vif-EloC-Cul5 (PDB ID: 4N9F), Skp2-
Skp1-Cul1 (PDB ID: 1LDK), and KLHL11-Cul3 (PDB ID: 4AP2) in ribbon representations with semitransparent surface shown for the cullins. Proteins are colored
as in the label above each panel.
(B) Conserved interactions of the three-protein interface involving adaptor protein-substrate receptor-helix a2 of cullin. Each region is marked in (A) with a black
asterisk and with the point of view pointed out by the left arrow.
(C) Charge complementary at the binary cullin-substrate receptor interface. Cullins are shown as electrostatic surfaces. Each region is marked in (A) with a blue
asterisk and with the point of view pointed out by the right arrow.main-chain carbonyl of H213 and the hydroxyl group of the T216
side chain. For Vif-Cul5, the electrostatic interaction involves the
loop following helix a2 of Cul5 because of the noncanonical
cullin-binding motif of Vif. This interaction nonetheless lies on
the same interface as those involving helix a5 of the cullins.
Notably, the polarity of the charge interaction in VHL-Cul2 is
the inverse of that in Cul5 complexes. This may explain why
VHL binds only to a Cul2 CRL, even although the same adaptor
protein, EloC, is used for both Cul2 and Cul5 CRLs. Thus,
electrostatic complementarity can influence the cullin selectivity
of a CRL.
DISCUSSION
VHL recruits a CRL to polyubiquitinate the transcription factor
HIF-1a, essential for the cellular response to hypoxia, for protea-
some-mediated degradation. While VHL is part of a CRL that
contains EloBC, the common adaptor component in a number
of Cul5-containing CRLs, it specifically recruits Cul2 over Cul5.
Prior to this report, there were no bona fide three-dimensional
structural data on Cul2 or VHL-Cul2 complexes, and the mech-
anism bywhich VHL specifically recruits Cul2 to target HIF-1a re-
mained unknown. Our structural and biochemical studies of the
VHL-EloBC-Cul2N complex illuminate how the E3 ligase is
assembled to ubiquitylate HIF-1a, demonstrate that CRLs have446 Structure 23, 441–449, March 3, 2015 ª2015 Elsevier Ltd All righa conserved overall architecture with some flexibility, and iden-
tify specific regions that help explain cullin selectivity.
CRLs exhibit a conserved overall architecture that has plas-
ticity to fine-tune the specific recruitment of different cullins.
The three-dimensional structures of the E3 ligase components
(i.e. Skp1-F box and EloBC-SOCS box) are more conserved
than their primary sequences. However, within this common
architecture, there exists some degree of variation to enable
cullin selection. Although both Cul2 and Cul5 CRLs contain
EloC as an adaptor protein, different residues in EloC engage
specific residues of Cul2 or Cul5 (Figure 3C). This difference,
together with the different substrate receptor protein compo-
nents (VHL, SOCS2, or Vif), determines whether Cul2 or Cul5 is
recruited to the CRL.
The interactions between substrate receptors and cullins are
variable but maintain conserved electrostatic features. SOCS
box substrate receptors contain either a canonical cullin box
(SOCS2 or VHL) or novel motif (Vif), which recruit a cullin. The
conserved cullin box sequences are very similar (Figure 1), mak-
ing it difficult to predict how specificity is conferred. Conversely,
residues actually making contact with the cullins can be outside
the cullin box and are not conserved. Our structural analysis
shows that of the conserved VHL cullin box residues (Figure 1),
only V181 interacts with Cul2. The remaining conserved residues
act as a scaffold to maintain the correct architecture so thatts reserved
other, nonconserved residues are oriented to recruit Cul2. This
introduces flexibility in the orientation of cullins with respect to
the substrate receptors, allowing for different regions or faces
of cullins to be accessed. Nevertheless, electrostatic interac-
tions, i.e., charge complementarity at the substrate receptor-
cullin interface (Figure 5C), are important in determining cullin
specificity. Comparison of the various substrate receptor-cullin
complexes reveals binding diversity on a common scaffold and
helps explain the varying affinities between substrate receptors
and cullins (Babon et al., 2009).
Our data provide a structural model to help understand the as-
sembly of the VHL-EloBC-Cul2 E3 ligase for HIF-1a degradation
and the associated pathogenesis of VHL disease. Various muta-
tions in VHL, such as K159E and multiple different substitutions
of L163, L184, or L188, cause VHL disease (Figure 1) (Nord-
strom-O’Brien et al., 2010). While residues L163, L184, and
L188 of VHL do not interact with EloC or Cul2, they are involved
in orienting the VHL SOCS box to interact with EloC/Cul2. Muta-
tions at these residues would perturb the correct orientation and/
or architecture of the SOCS box and consequently interfere with
the appropriate positioning of VHL residues, which are respon-
sible for Cul2 binding. The K159E mutation, while preventing
the neddylation of VHL, also destabilizes the VHL-Cul2 interac-
tion (Figure 4C).
Inhibition of the HIF pathway to increase endogenous erythro-
poietin production has been investigated as a therapy to treat
chronic anemia (Muchnik and Kaplan, 2011). Much of the focus
to date has centered on disrupting the VHL-HIF-1a interface us-
ing small molecules (Buckley et al., 2012; Galdeano et al., 2014;
Van Molle et al., 2012). The targeting of the VHL-Cul2 or EloC-
Cul2 interaction to prevent HIF downregulation has not yet
been explored. We have identified novel binding sites between
Cul2-EloC and Cul2-VHL, where mutations at these interfaces
disrupt the formation of the CRL. For example, the unique bind-
ing pocket on EloC where the N terminus of Cul2 interacts is an
attractive target for a small molecule that would inhibit the VHL-
mediated HIF-1a downregulation pathway. These findings can
aid in the development of novel compounds for the therapeutic
intervention of chronic anemia.EXPERIMENTAL PROCEDURES
Cloning
VHL (residues 1–213, a gift from Craig Crews, Yale University) was cloned into
the pET28 vector (Novagen) with a 6xHis tag or into the pGEX 4T-1 vector (GE
Healthcare) with a GST tag. EloB (residues 1–118) and EloC (residues 17–112)
were cloned into the pACYCDuet vector (a gift from Alex Bullock, University
of Oxford, Oxford, United Kingdom). Cul2 (a gift from Craig Crews, Yale Uni-
versity) residues 1–163 were cloned into the pRSFDuet-1 vector with a
6xHis tag (Novagen) and residues 1–277 were cloned into the pMAT9S vector
(Peranen et al., 1996) with an N-terminal 6xHis-MBP tag. Point mutations were
made by QuickChange site-directed mutagenesis (Stratagene) and verified by
sequencing.
Expression and Purification
Plasmids encoding 6xHis tagged VHL, EloB, EloC, and 6xHis tagged Cul2 (res-
idues 1–163) were transformed into Escherichia coli BL-21(DE3) cells and
coexpression of the proteins was induced with 0.5 mM isopropyl-b-D-thioga-
lactopyranoside (IPTG) at 16C in Terrific Broth. Plasmids encoding GST-
tagged VHL, EloB, and EloC were transformed into E. coli BL-21(DE3) cells
with coexpression induced with 0.5 mM IPTG at 25C in Luria Broth. TheStructure 23,plasmid encoding 6xHis-MBP-Cul2 (residues 1–277) was cotransformed
with the pGro7 vector (Takara Bio), which encodes the chaperone proteins
groES and groEL, into E. coli BL-21(DE3) cells. Chaperone expression was
induced by addition of L-(+)-arabinose at 2 mg/ml, and 6xHis-MBP-Cul2
expression was induced with 0.5 mM IPTG at 16C in Terrific Broth.
Cells were harvested and lysed by amicrofluidizer. The solutionwas clarified
by centrifugation and the lysate was applied to an Ni-NTA, GSTrap, or
MBPTrap column and further purified to homogeneity by anion exchange
and size exclusion chromatography. Proteins were analyzed after each step
by SDS-PAGE.
Crystallization and Data Collection
Initial crystals were obtained by the microbatch under-oil method (Chayen
et al., 1990). Crystals were further optimized by hanging-drop vapor diffusion
with equals volumes (2 ml) of protein (5 mg/ml in 50 mM Tris [pH 8], 150 mM
NaCl, 0.1 mM Tris-(2-carboxyethyl)phosphine) and the precipitant solution
(5 M Na formate). Crystals formed overnight at 25C. Crystals were cryopro-
tected using the precipitant solution containing 20% glycerol and then flash
frozen in liquid nitrogen. Diffraction data were collected at beamline X29 at
the National Synchrotron Light Source, Brookhaven National Laboratory.
Data were processed and scaled with HKL2000 (Otwinowski and Minor,
1997). Crystals are in P3221 space group and diffracted to a resolution of
3.2 A˚. The data statistics are summarized in Table 1.
Structure Determination and Refinement
The structure was solved by molecular replacement using PHASER (McCoy
et al., 2007) with search models of VHL-EloBC (Protein Data Bank [PDB] ID:
1LM8) (Min et al., 2002) and Cul5 containing residues 12–159 (PDB ID:
2WZK) (Muniz et al., 2013). One complex was identified in the asymmetric
unit. Iterative rounds of model building in COOT (Emsley and Cowtan, 2004)
and refinement in REFMAC5 (Vagin et al., 2004) and Phenix (Adams et al.,
2010) were carried out. The B factors of the refined model were high (123 A˚2
in average), presumably as a result of the inherent property of the crystal,
such as packing defects. Data sharpening was performed (Liu and Xiong,
2014) to enhance the electron density map and facilitate model building. The
high-resolution VHL-EloBC structure (PDB ID: 1LM8) (Min et al., 2002) was
used as a reference model during refinement. The final model has an Rwork/
Rfree of 22.1%/25.0%. Refinement statistics are summarized in Table 1.
In Vitro GST Pull-Down Assay
The purified GST-VHL-EloBC (0.2 mg) and MBP-Cul2 (0.2 mg) proteins or
respective mutants were mixed in a final volume of 200 ml and incubated at
room temperature for 1 hr with 0.2 ml of GST resin. The protein solution was
then loaded onto a small gravity-flow column. Flow-through was collected
and the resin was extensively washed with 5 3 1 ml of GST binding buffer
(50 mM Tris [pH 7.2], 150 mM NaCl, 0.1 mM Tris-(2-carboxyethyl)phosphine).
The bound proteins were eluted with 53 0.2 ml of GST elution buffer contain-
ing 10 mM reduced glutathione. The eluted proteins were analyzed by SDS-
PAGE stained with Coomassie blue.
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